AU2011905368A0 - Dosing regime for apolipoprotein formulations - Google Patents

Dosing regime for apolipoprotein formulations

Info

Publication number
AU2011905368A0
AU2011905368A0 AU2011905368A AU2011905368A AU2011905368A0 AU 2011905368 A0 AU2011905368 A0 AU 2011905368A0 AU 2011905368 A AU2011905368 A AU 2011905368A AU 2011905368 A AU2011905368 A AU 2011905368A AU 2011905368 A0 AU2011905368 A0 AU 2011905368A0
Authority
AU
Australia
Prior art keywords
dosing regime
apolipoprotein formulations
apolipoprotein
formulations
regime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011905368A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of AU2011905368A0 publication Critical patent/AU2011905368A0/en
Priority to RU2017129700A priority Critical patent/RU2776110C2/en
Priority to US14/364,764 priority patent/US20140378376A1/en
Priority to RU2014129505A priority patent/RU2014129505A/en
Priority to CA2857968A priority patent/CA2857968A1/en
Priority to PL12859136.9T priority patent/PL2793913T3/en
Priority to ES12859136T priority patent/ES2955110T3/en
Priority to CN201280063210.4A priority patent/CN104010646A/en
Priority to BR112014014403A priority patent/BR112014014403A2/en
Priority to CN202110675512.8A priority patent/CN113398245A/en
Priority to KR1020197019295A priority patent/KR20190084334A/en
Priority to NZ624558A priority patent/NZ624558B2/en
Priority to KR1020207009276A priority patent/KR20200037879A/en
Priority to EP12859136.9A priority patent/EP2793913B1/en
Priority to SG11201402556RA priority patent/SG11201402556RA/en
Priority to PCT/AU2012/001345 priority patent/WO2013090978A1/en
Priority to DK12859136.9T priority patent/DK2793913T3/en
Priority to MX2014006589A priority patent/MX2014006589A/en
Priority to KR1020147020291A priority patent/KR20140107536A/en
Priority to AU2012310259A priority patent/AU2012310259C1/en
Priority to JP2014547627A priority patent/JP6144276B2/en
Priority to IL233236A priority patent/IL233236A0/en
Priority to HK15100165.2A priority patent/HK1199813A1/en
Priority to US15/054,358 priority patent/US20160175392A1/en
Priority to JP2017045676A priority patent/JP2017128586A/en
Abandoned legal-status Critical Current

Links

AU2011905368A 2011-12-21 2011-12-21 Dosing regime for apolipoprotein formulations Abandoned AU2011905368A0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
JP2014547627A JP6144276B2 (en) 2011-12-21 2012-11-02 Dosing schedule for apolipoprotein preparations
NZ624558A NZ624558B2 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
SG11201402556RA SG11201402556RA (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
EP12859136.9A EP2793913B1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
CA2857968A CA2857968A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
US14/364,764 US20140378376A1 (en) 2011-12-21 2012-11-02 Dosage Regime for Apolipoprotein Formulations
ES12859136T ES2955110T3 (en) 2011-12-21 2012-11-02 Dosing Regimen for Apolipoprotein Formulations
CN201280063210.4A CN104010646A (en) 2011-12-21 2012-11-02 Dosage Regime For Apolipoprotein Formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
CN202110675512.8A CN113398245A (en) 2011-12-21 2012-11-02 Dosage regimen for apolipoprotein formulations
KR1020197019295A KR20190084334A (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
RU2017129700A RU2776110C2 (en) 2012-11-02 Dosing scheme for apolipoprotein compositions
KR1020207009276A KR20200037879A (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
RU2014129505A RU2014129505A (en) 2011-12-21 2012-11-02 DOSAGE SCHEME FOR APOLIPOPROTEIN COMPOSITIONS
PL12859136.9T PL2793913T3 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
BR112014014403A BR112014014403A2 (en) 2011-12-21 2012-11-02 dosage regimen for apolipoprotein formulations
DK12859136.9T DK2793913T3 (en) 2011-12-21 2012-11-02 DOSAGE SCHEDULE FOR APOLYPOPROTEIN FORMULATIONS
MX2014006589A MX2014006589A (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations.
KR1020147020291A KR20140107536A (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
AU2012310259A AU2012310259C1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
IL233236A IL233236A0 (en) 2011-12-21 2014-06-18 Dosage regime for apolipoprotein formulations
HK15100165.2A HK1199813A1 (en) 2011-12-21 2015-01-07 Dosage regime for apolipoprotein formulations
US15/054,358 US20160175392A1 (en) 2011-12-21 2016-02-26 Dosage regime for apolipoprotein formulations
JP2017045676A JP2017128586A (en) 2011-12-21 2017-03-10 Dosage regime for apolipoprotein formulations

Publications (1)

Publication Number Publication Date
AU2011905368A0 true AU2011905368A0 (en) 2012-01-19

Family

ID=

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
EP2706987B8 (en) Pharmaceutical compositions
HRP20181896T1 (en) Pharmaceutical formulations
GB201113662D0 (en) Pharmaceutical compositions
HK1199824A1 (en) Pharmaceutical compositions
GB201118232D0 (en) Pharmaceutical composition
EP2702989A4 (en) Stable pharmaceutical composition
HK1189158A1 (en) Pharmaceutical composition
GB201118181D0 (en) Pharmaceutical compositions
EP2727593A4 (en) Nicorandil-containing pharmaceutical composition
HK1199813A1 (en) Dosage regime for apolipoprotein formulations
EP2711010A4 (en) Pharmaceutical composition
HUP1100444A2 (en) Pharmaceutical composition
EP2714715A4 (en) Pharmaceutical compositions
AU2011905368A0 (en) Dosing regime for apolipoprotein formulations
HUP1100445A2 (en) Pharmaceutical composition
AU2011904970A0 (en) Pharmaceutical compositions
AU2011904699A0 (en) Pharmaceutical compositions
AU2011905393A0 (en) Pharmaceutical Composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201111577D0 (en) Pharmaceutical formulations